약물 코팅 풍선 시장 규모, 점유율, 동향 분석 : 제품 종류별, 용도별, 최종사용자별, 지역별 - 세계 기회 분석과 산업 예측(2026-2036년)

The global Drug-Coated Balloon Market is projected to grow from USD 1.28 billion in 2026 to USD 2.95 billion by 2036, registering a CAGR of 8.7% during the forecast period. The report provides a comprehensive assessment of the global market by evaluating current industry dynamics, technological advancements, competitive developments, and future growth opportunities across major product types, applications, end users, and geographic regions.

Drug-coated balloons (DCBs) have emerged as an important advancement in endovascular intervention by enabling localized delivery of antiproliferative drugs to diseased blood vessels without leaving behind a permanent implant. These devices have gained widespread clinical acceptance for the treatment of peripheral artery disease (PAD), coronary in-stent restenosis (ISR), and other complex vascular lesions due to their ability to reduce restenosis, preserve vessel anatomy, and improve long-term clinical outcomes. Continuous advancements in balloon coating technologies, drug delivery mechanisms, catheter design, and lesion preparation techniques have significantly enhanced procedural success, drug transfer efficiency, and treatment durability. In parallel, the increasing global burden of cardiovascular diseases, rising prevalence of diabetes and peripheral vascular disorders, growing preference for minimally invasive vascular interventions, and expanding adoption of stent-less treatment strategies continue to create favorable conditions for market growth.

This report presents a detailed evaluation of the factors influencing market performance while providing strategic insights into industry trends, technology adoption, regulatory developments, reimbursement scenarios, and competitive positioning. It also examines evolving customer requirements, investment patterns, product innovation, commercialization strategies, and strategic collaborations adopted by industry participants. The study is designed to support strategic planning by providing reliable market intelligence and long-term forecasts for stakeholders operating across the drug-coated balloon value chain.

Market Dynamics

The market continues to expand due to the increasing prevalence of peripheral artery disease and coronary artery disease, growing demand for minimally invasive vascular interventions, and rising clinical preference for stent-less treatment approaches. Healthcare providers are increasingly adopting drug-coated balloons to reduce restenosis, improve vessel patency, and minimize complications associated with permanent metallic implants. The growing incidence of diabetes-related vascular complications, increasing procedural volumes in interventional cardiology and peripheral vascular interventions, expanding access to advanced catheterization laboratories, and continuous improvements in healthcare infrastructure are collectively driving the adoption of advanced drug-coated balloon technologies. Furthermore, favorable clinical evidence supporting the effectiveness of DCBs in treating complex vascular lesions continues to strengthen physician confidence and support sustained market growth.

Technological innovation remains one of the defining characteristics of this market. Continuous advancements in paclitaxel-coated and sirolimus-coated balloon technologies, novel drug carrier formulations, balloon surface coating techniques, catheter deliverability, and lesion preparation devices are transforming endovascular treatment procedures. These innovations enable more efficient drug transfer, improved balloon performance in complex anatomies, reduced vascular injury, and enhanced long-term clinical outcomes. Growing investments in next-generation sirolimus-coated balloon technologies, expansion of clinical indications, and increasing integration of advanced imaging and intravascular guidance systems are expected to accelerate product innovation and broaden the clinical applications of drug-coated balloons worldwide.

Despite favorable growth prospects, several factors continue to influence market expansion. The high cost associated with advanced drug-coated balloon technologies, stringent regulatory approval requirements, reimbursement variability across healthcare systems, and continued clinical scrutiny regarding long-term safety and effectiveness of certain drug formulations remain important barriers to broader market adoption. Healthcare providers also face challenges related to patient selection, lesion preparation, procedural complexity, and physician training while integrating newer-generation DCB technologies into routine clinical practice.

The market nevertheless presents considerable opportunities for manufacturers and investors. Increasing adoption of drug-coated balloons for coronary in-stent restenosis, expanding utilization in peripheral vascular interventions, growing healthcare investments across emerging economies, and continuous development of next-generation drug-delivery platforms are expected to support sustained market growth over the coming years. Strategic collaborations among medical device manufacturers, healthcare providers, research institutions, and interventional cardiology specialists are accelerating technology adoption while facilitating the development of innovative vascular treatment solutions. At the same time, market participants must address competitive pricing pressures, evolving regulatory requirements, rapidly advancing coating technologies, and the need to continuously demonstrate superior clinical outcomes through long-term evidence generation to maintain sustainable market leadership.

Segment Analysis

The report provides an extensive analysis of the drug-coated balloon market across product type, application, end user, and geography, enabling stakeholders to identify high-growth segments and emerging investment opportunities.

Based on product type, the market is analyzed across paclitaxel-coated balloons, sirolimus-coated balloons, and other drug-coated balloon technologies. Paclitaxel-coated balloons continue to account for a significant share of the market owing to their well-established clinical evidence, widespread regulatory approvals, and extensive use in peripheral artery disease (PAD) and coronary in-stent restenosis (ISR) interventions. Sirolimus-coated balloons are expected to witness the fastest growth during the forecast period due to increasing clinical adoption, favorable safety profile, and growing evidence supporting their long-term efficacy in coronary and peripheral vascular applications. Continuous innovation in drug formulations, coating technologies, and balloon delivery systems is expected to further enhance the performance and clinical utility of both product categories.

From an application perspective, the report evaluates peripheral artery disease (PAD), coronary artery disease (CAD), and other vascular applications. Peripheral artery disease continues to represent the largest application segment owing to the increasing prevalence of lower limb arterial disease, growing incidence of diabetes and chronic kidney disease, and widespread use of drug-coated balloons in femoropopliteal interventions. Coronary artery disease is expected to register substantial growth during the forecast period, supported by increasing adoption of drug-coated balloons for the treatment of in-stent restenosis, small vessel disease, bifurcation lesions, and other complex coronary interventions. Expanding clinical evidence and evolving treatment guidelines are further supporting the broader adoption of drug-coated balloon technologies across multiple vascular applications.

The study further analyzes market performance across major end-user categories. Hospitals and cardiac centers continue to account for the largest share of the market owing to their advanced cardiovascular infrastructure, availability of experienced interventional cardiologists and vascular specialists, and higher procedural volumes involving complex endovascular interventions. Cardiac catheterization laboratories are also witnessing significant growth as healthcare providers continue expanding specialized interventional cardiology services and adopting advanced imaging-guided vascular procedures. Ambulatory surgical centers are expected to register notable growth during the forecast period due to the increasing shift toward minimally invasive outpatient cardiovascular interventions, improved procedural efficiency, and growing emphasis on cost-effective patient care.

Regional Analysis

The report offers a comprehensive assessment of market performance across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Each regional analysis considers cardiovascular disease prevalence, healthcare infrastructure, reimbursement frameworks, regulatory environments, technology adoption, physician expertise, and competitive intensity to provide a holistic understanding of regional growth dynamics.

North America currently represents a significant share of the global market owing to its advanced cardiovascular care infrastructure, widespread adoption of minimally invasive vascular interventions, favorable reimbursement policies, increasing prevalence of peripheral and coronary artery diseases, and the strong presence of leading medical device manufacturers. Continuous technological innovation, expanding clinical evidence supporting drug-coated balloon therapies, and growing investments in interventional cardiology continue to strengthen the region's market position.

Europe continues to demonstrate stable market growth, supported by increasing adoption of endovascular treatment procedures, favorable clinical guidelines, expanding access to specialized cardiovascular care, and ongoing investments in healthcare modernization. The region has also witnessed early adoption of advanced drug-coated balloon technologies, particularly for peripheral artery disease and coronary in-stent restenosis, further supporting market expansion.

Asia-Pacific is expected to register the fastest growth during the forecast period due to the rapidly increasing burden of cardiovascular diseases, expanding healthcare expenditure, improving access to advanced interventional cardiology services, and rising adoption of minimally invasive vascular procedures across major developing economies. Increasing awareness regarding early diagnosis and treatment of vascular diseases, coupled with expanding catheterization laboratory infrastructure and improving physician expertise, is creating significant growth opportunities for market participants throughout the region.

Latin America and the Middle East & Africa are also expected to present attractive long-term opportunities as governments continue investing in healthcare infrastructure, improving access to specialized cardiovascular care, and promoting the adoption of advanced medical technologies. Increasing diagnosis rates of peripheral and coronary artery diseases, expanding availability of minimally invasive vascular interventions, and growing collaborations between healthcare providers and medical device manufacturers are expected to further support market growth across these emerging regions.

Competitive Landscape

The report presents a detailed evaluation of the competitive landscape, offering valuable insights into the strategic positioning of major industry participants. It examines company portfolios, business strategies, technological capabilities, product launches, mergers and acquisitions, partnerships, collaborations, geographic expansion initiatives, research and development investments, and other significant corporate developments shaping the competitive environment.

Company benchmarking enables stakeholders to compare market participants based on their product portfolios, innovation capabilities, regional presence, strategic priorities, and competitive strengths. The report also evaluates the evolving competitive intensity resulting from continuous product innovation, increasing adoption of minimally invasive endovascular procedures, expansion of drug-coated balloon indications, and growing investments in next-generation drug delivery technologies. As demand for effective stent-less vascular interventions continues to increase, manufacturers are focusing on developing advanced balloon coating technologies, improving drug transfer efficiency, enhancing catheter deliverability, and generating robust long-term clinical evidence while strengthening their global market presence through strategic collaborations, physician education initiatives, and continuous technological innovation.

Key companies profiled in the report include B. Braun SE, Becton, Dickinson and Company, Boston Scientific Corporation, Medtronic plc, Koninklijke Philips N.V., BIOTRONIK SE & Co. KG, Cordis Corporation, Concept Medical Inc., Acotec Scientific Holdings Limited, and iVascular S.L.U.

How This Report Helps

• Provides reliable market size estimates and long-term growth forecasts.
• Evaluates major market drivers, restraints, opportunities, challenges, and emerging industry trends.
• Identifies high-growth product type, application, end-user, and regional segments.
• Assesses evolving technology adoption and innovation across the drug-coated balloon ecosystem.
• Benchmarks leading companies based on their product portfolios, strategic initiatives, and competitive positioning.
• Supports business expansion, investment planning, partnership evaluation, and product development strategies.
• Delivers actionable insights for medical device manufacturers, healthcare providers, distributors, investors, consultants, and other industry stakeholders.

Key Questions Answered

• What is the current size of the global drug-coated balloon market, and what is its projected growth through 2036?
• Which factors are driving, restraining, and influencing market growth?
• What opportunities and challenges are expected to shape the industry during the forecast period?
• Which product type, application, end-user, and regional segments are expected to witness the strongest growth?
• Which regions are expected to offer the most attractive business opportunities?
• Who are the leading companies operating in the market, and how are they strengthening their competitive positions?
• What recent technological developments, product launches, partnerships, acquisitions, and strategic initiatives are influencing the competitive landscape?
• How can stakeholders leverage market intelligence from this report to support strategic planning, investment decisions, market expansion, and product development initiatives?

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Scope
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Data Sources
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research
• 2.3. Market Size Estimation
  • 2.3.1. Bottom-up Approach
  • 2.3.2. Top-down Approach
• 2.4. Assumptions

3. Executive Summary

• 3.1. Market Snapshot
• 3.2. Segmental Summary
• 3.3. Regional Summary
• 3.4. Competitive Snapshot

4. Market Overview

• 4.1. Introduction
• 4.2. Market Dynamics
  • 4.2.1. Drivers
    • 4.2.1.1. Growing Clinical Preference for 'Stent-less' Therapies in Peripheral Arteries
    • 4.2.1.2. Rising Prevalence of Diabetes and Associated Complex Small Vessel Disease
  • 4.2.2. Restraints
    • 4.2.2.1. Lingering Safety Concerns and Regulatory Scrutiny Regarding Paclitaxel-Coated Devices
    • 4.2.2.2. High Cost of DCBs and Budgetary Constraints in Healthcare Systems
  • 4.2.3. Opportunities
    • 4.2.3.1. Expansion into Primary Coronary Interventions and Small Vessel Disease
    • 4.2.3.2. Development of Next-Generation Sirolimus-Coated Balloons with Advanced Nanotechnology
  • 4.2.4. Trends
    • 4.2.4.1. Rapid Clinical Adoption of Sirolimus-Coated Balloons in Complex Interventions
    • 4.2.4.2. Shift Toward Outpatient Peripheral Vascular Procedures in ASCs
• 4.3. Porter's Five Forces Analysis
• 4.4. Regulatory Outlook and Reimbursement Landscape
• 4.5. Value Chain Analysis

5. Global Drug-Coated Balloon Market, by Product Type

• 5.1. Paclitaxel-Coated Balloons
• 5.2. Sirolimus-Coated Balloons

6. Global Drug-Coated Balloon Market, by Application

• 6.1. Peripheral Artery Disease (PAD)
• 6.2. Coronary In-Stent Restenosis (ISR)
• 6.3. Coronary Small Vessel Disease
• 6.4. Neurovascular Interventions
• 6.5. Others

7. Global Drug-Coated Balloon Market, by End User

• 7.1. Hospitals & Cardiac Centers
• 7.2. Ambulatory Surgical Centers (ASCs)
• 7.3. Specialty Clinics

8. Global Drug-Coated Balloon Market, by Geography

• 8.1. North America
  • 8.1.1. U.S.
  • 8.1.2. Canada
• 8.2. Europe
  • 8.2.1. Germany
  • 8.2.2. U.K.
  • 8.2.3. France
  • 8.2.4. Italy
  • 8.2.5. Spain
  • 8.2.6. Rest of Europe
• 8.3. Asia Pacific
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. South Korea
  • 8.3.5. Rest of Asia Pacific
• 8.4. Latin America
  • 8.4.1. Brazil
  • 8.4.2. Argentina
  • 8.4.3. Mexico
  • 8.4.4. Rest of Latin America
• 8.5. Middle East & Africa
  • 8.5.1. UAE
  • 8.5.2. Saudi Arabia
  • 8.5.3. Rest of Middle East & Africa

9. Competitive Landscape

• 9.1. Key Players Strategies
• 9.2. Market Share Analysis
• 9.3. Strategic Developments
• 9.4. Competitive Benchmarking

10. Company Profiles

• 10.1. Medtronic plc
• 10.2. Boston Scientific Corporation
• 10.3. Becton, Dickinson and Company (BD)
• 10.4. Abbott Laboratories
• 10.5. B. Braun Melsungen AG
• 10.6. Cook Medical
• 10.7. Terumo Corporation
• 10.8. Koninklijke Philips N.V. (Royal Philips)
• 10.9. Biotronik SE & Co. KG
• 10.10. Cordis (Hellman & Friedman)
• 10.11. Concept Medical Inc.
• 10.12. Acotec Scientific Holdings Limited
• 10.13. Lepu Medical Technology (Beijing) Co., Ltd.
• 10.14. iVascular S.L.U.
• 10.15. Cardionovum GmbH
• 10.16. Eurocor Tech GmbH
• 10.17. Hexacath
• 10.18. Surmodics, Inc.
• 10.19. Teleflex Incorporated
• 10.20. Endocor GmbH

11. Appendix

• 11.1. Disclaimer

12. Key Questions Answered